Antibiotic Prophylaxis, Wound Infection, Groin Hernia
Conditions
Keywords
Groin hernia, Postoperative complications, Wound infection, Surgical site infection, High-risk patients
Brief summary
This study aims to investigate the impact of antibiotic prophylaxis on reducing wound infection rates following open repair of primary elective groin hernias in high-risk patients.
Detailed description
This study will be a randomized controlled trial involving high-risk patients undergoing open repair of primary elective groin hernias. Participants will be randomized into two groups: one receiving antibiotic prophylaxis and the other serving as the control group. The study will assess the incidence of wound infections postoperatively in both groups to determine the effectiveness of antibiotic prophylaxis in lowering infection rates.
Interventions
* Medication: Cefazolin * Dosage: 1 gram * Administration Timing: A single dose will be administered preoperatively.
Sponsors
Aleppo University Hospital Resident Team
University of Aleppo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Volunteer to participate in the study. * Elderly patients aged over 60 years. * Patients with Diabetes. * Or obese patients with a BMI greater than 35. * Or immunocompromised patients. * Or American Society of Anesthesiologists (ASA) physical status classification 2 or more, with a history of more than 10 years.
Exclusion criteria
* Non-cooperative patients for regular follow-up. * Therapeutic Indication for.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Complication Rate | up to 30 days after the surgery. | Overall complication rate; graded by the Clavien- Dindo complications classification system |
| Wound infection/ Surgical site infection | up to 30 days after the surgery. | has been defined and classified as superficial incisional, deep incisional, and organ/ space\_ surgical site infection by the Centers for Disease Control and Prevention (CDC) (Anderson 2014; Ban 2017; Berríos-Torres 2017). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality Rate | up to 30 days after the surgery. | The measure of the number of deaths at the end of the study. |
| Hospital stay | up to 30 days after the surgery. | In days: Number of days, patient in hospital since admission. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Other Adverse events | up to 30 days after the surgery. | Any adverse events will be observed during the follow-up period. |
Countries
Syria
Contacts
Primary ContactMohammad H Nabhan, M.D
Outcome results
None listed